| MicroRNA‐506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation O Erice, P Munoz‐Garrido, J Vaquero, MJ Perugorria, ... Hepatology 67 (4), 1420-1440, 2018 | 106 | 2018 |
| TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms A Esparza-Baquer, I Labiano, O Sharif, A Agirre-Lizaso, F Oakley, ... Gut 70 (7), 1345-1361, 2021 | 100 | 2021 |
| Soluble adenylyl cyclase regulates bile salt‐induced apoptosis in human cholangiocytes JC Chang, S Go, DR de Waart, P Munoz‐Garrido, U Beuers, ... Hepatology 64 (2), 522-534, 2016 | 86 | 2016 |
| Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease P Munoz-Garrido, JJG Marin, MJ Perugorria, AD Urribarri, O Erice, E Sáez, ... Journal of hepatology 63 (4), 952-961, 2015 | 80 | 2015 |
| Post-translational regulation of the type III inositol 1, 4, 5-trisphosphate receptor by miRNA-506 M Ananthanarayanan, JM Banales, MT Guerra, C Spirli, P Munoz-Garrido, ... Journal of Biological Chemistry 290 (1), 184-196, 2015 | 80 | 2015 |
| Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression O Erice, I Labiano, A Arbelaiz, A Santos-Laso, P Munoz-Garrido, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1864 (4 …, 2018 | 74 | 2018 |
| Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases AD Urribarri, P Munoz-Garrido, MJ Perugorria, O Erice, ... Gut 63 (10), 1658-1667, 2014 | 64 | 2014 |
| Causes of hOCT1‐dependent cholangiocarcinoma resistance to sorafenib and sensitization by tumor‐selective gene therapy E Lozano, RIR Macias, MJ Monte, M Asensio, S Del Carmen, ... Hepatology 70 (4), 1246-1261, 2019 | 62 | 2019 |
| Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: a multicentre retrospective cohort study I Guerra, L Bujanda, J Castro, O Merino, J Tosca, B Camps, A Gutiérrez, ... Journal of Crohn's and Colitis 13 (12), 1492-1500, 2019 | 55 | 2019 |
| Current and novel therapeutic opportunities for systemic therapy in biliary cancer JJG Marin, MG Prete, A Lamarca, S Tavolari, A Landa-Magdalena, ... British journal of cancer 123 (7), 1047-1059, 2020 | 51 | 2020 |
| Epigenome dysregulation in cholangiocarcinoma CJ O'Rourke, P Munoz-Garrido, EL Aguayo, JB Andersen Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1864 (4 …, 2018 | 49 | 2018 |
| Molecular targets in cholangiocarcinoma CJ O’Rourke, P Munoz‐Garrido, JB Andersen Hepatology 73, 62-74, 2021 | 37 | 2021 |
| MicroRNAs in biliary diseases P Munoz-Garrido, MGF de Barrena, E Hijona, M Carracedo, JJG Marín, ... World Journal of Gastroenterology: WJG 18 (43), 6189, 2012 | 35 | 2012 |
| Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: new therapeutic targets A Santos‐Laso, L Izquierdo‐Sanchez, PM Rodrigues, BQ Huang, ... Liver International 40 (7), 1670-1685, 2020 | 26 | 2020 |
| The protease‐inhibitor SerpinB3 as a critical modulator of the stem‐like subset in human cholangiocarcinoma M Correnti, A Cappon, M Pastore, B Piombanti, G Lori, DVPN Oliveira, ... Liver International 42 (1), 233-248, 2022 | 24 | 2022 |
| The jigsaw of dual hepatocellular–intrahepatic cholangiocarcinoma tumours P Munoz-Garrido, PM Rodrigues Nature Reviews Gastroenterology & Hepatology 16 (11), 653-655, 2019 | 22 | 2019 |
| MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells L Duwe, P Munoz-Garrido, M Lewinska, J Lafuente-Barquero, L Satriano, ... Journal of hepatology 78 (2), 364-375, 2023 | 17 | 2023 |
| Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer D Høgdall, CJ O’Rourke, FO Larsen, S Zarforoushan, TD Christensen, ... Journal of hepatology 77 (4), 1047-1058, 2022 | 15 | 2022 |
| New advances in the molecular mechanisms driving biliary fibrosis and emerging molecular targets A Santos-Laso, P Munoz-Garrido, M Felipe-Agirre, L Bujanda, ... Current drug targets 18 (8), 908-920, 2017 | 14 | 2017 |
| working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European Network for the study of Cholangiocarcinoma (ENSCCA). Current and novel therapeutic … JJG Marin, MG Prete, A Lamarca, S Tavolari, A Landa-Magdalena, ... Br J Cancer 123 (7), 1047-1059, 2020 | 12 | 2020 |
